Listar por autor "Hierro Carbó, Cinta"
Mostrando ítems 1-3 de 3
-
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
Piha-Paul, Sarina; Geva, Ravit; Tan, Tira; Lim, Darren Wan-Teck; Hierro Carbó, Cinta; Doi, Toshikiko (BMJ, 2021-08) -
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
Matos Garcia, Ignacio; Villacampa Javierre, Guillermo; Hierro Carbó, Cinta; Martín Liberal, Juan Jesús; Berche, Roger; Pedrola Gómez, Anna; Braña Garcia, Irene; Azaro Pedrazzoli, Analía Beatriz; Vieito Villar, Maria; Saavedra Santa Gadea, Omar; Gardeazabal, Itziar; Hernando Calvo, Alberto; Alonso-Casal, Guzman; Galvao, Vladimir; Ochoa de Olza Amat, Maria; Ros Montañá, Fco. Javier; Viaplana Donato, Cristina; Muñoz Couselo, Eva; Elez Fernandez, Mª Elena; Rodon Ahnert, Jordi; Saura Manich, Cristina; Macarulla Mercadé, Teresa; Oaknin Benzaquen, Ana Mazaltob; Carles Galceran, Joan; Felip Font, Enriqueta; Tabernero Caturla, Josep; Dienstmann, Rodrigo; Garralda Cabanas, Elena (Elsevier, 2021-09) -
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
Gazzah, A.; Bedard, Philippe L.; Hierro Carbó, Cinta; Kang, Yoon-Koo; Abdul Razak, A.; Ryu, M.-H.; Tabernero Caturla, Josep (Elsevier, 2022-04)